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The hepatitis C virus (HCV) is responsible for 60-70% of chronic hepatitis and 30% of cirrhosis, end
stage liver disease, and liver cancer in the United States. Approximately 1.8% or close to 4.5 million
Americans are infected with HCV, and HCV causes an estimated 8,000-10,000 deaths each year in this
country.  75-85% of those infected with HCV develop chronic liver disease (1). Chronic infection varies
in severity and clinical course.  Many of those infected will have normal liver enzymes and no clinical
symptoms. Approximately 50% of these individuals are unaware of their HCV infection (2). Of those who
develop chronic liver disease, perhaps 20% will eventually progress to cirrhosis and several percent will
develop liver carcinoma (1).
Among individuals who have persistent HCV infection, 80% are asymptomatic, despite intermittent
viremia and abnormal fluctuations of their liver function tests. These individuals have the capacity to
infect others.  HCV is responsible for approximately 40% of the 25,000 annual deaths in the U.S. from
chronic liver disease (1). HCV is grouped into six genotypes and more than 90 subtypes; genotypes 1a
and 1b are more common in the United States and less responsive to antiviral therapy.
HCV Epidemiology in Corrections
During the 1980’s an average of 230,000 new HCV infections occurred each year in the US (3). The
number of new infections declined after the introduction of improved methods for the detection of HCV
in the blood supply. 
Currently, most HCV transmission is associated with injection drug use (IDU). 79% of current IDUs have
HCV infection (3). Young IDUs acquire HCV infection at rates four times higher than they acquire HIV;
after five years of injection drug use, 90% of users are HCV infected. Non-Hispanic blacks and African
Americans have higher rates of HCV infection and chronic disease than whites; most cases of HCV
infection are found among persons who are male, members of minority populations, and 30 to 49 years
of age (3). 
Given the linkages between HCV infection and drug
use, gender, age, and minority populations, it is not
surprising that almost one third (1.4 million) of the 4
million individuals in the United States who are
believed to be infected with HCV pass through cor-
rectional facilities each year (2). The prevalence of
HCV infection among U.S. prisoners is at least 10-
fold higher than the estimated prevalence of 2% in
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HCV infection
75-85% develop 
chronic HCV 
20% develop cirrhosis 
and liver failure
15-25% Resolve Infection
80% of these have asymptomatic intermittent
viremia/LFT fluctuation
1-4% develop hepatocellular carcinoma
Figure 1. Patterns of Disease in Hepatitis C Infection
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the general population (4, 2). Where surveys
have been carefully performed, HCV infec-
tion rates among inmates have ranged
between 30 and 40% (5). Estimates of HCV
infection in state correctional facilities range
from 28% (Texas) to 54% among women in
California (see Figure 2). HIV-infected incar-
cerated women exhibit a slightly higher HCV
co-infection rate than HIV-infected incarcer-
ated men (see Figure 2).
Who should get tested 
for HCV?
The CDC specifically recommends testing
persons in settings with potentially high pro-
portions of injection drug users (see Table 1).
For instance, the CDC lists correctional insti-
tutions, HIV counseling and testing sites, or
drug and STD treatment programs as poten-
tial settings (3). It should be noted that sexu-
al transmission and maternal-infant trans-
mission is uncommon. Testing should be
accompanied by appropriate counseling and
medical follow-up. Even if treatment is not to
be initiated, persons who test positive for
HCV should be given information about risk
and prevention of disease and risk of trans-
mission to others. Co-infection with HIV has
been said to reduce HCV antibody test accu-
racy, however a recent study by Thio et al.
suggested that third-generation antibody
based assays are sufficiently accurate for
diagnosis (13).
Treatment Options
There are two basic approaches to the treat-
ment of HCV: monotherapy with interferon
alpha, or combination therapy with interferon
alpha and ribavirin.  Combination therapy is
more expensive and has a higher incidence
of side effects, but is significantly more effec-
tive. When interferon is used alone, approxi-
mately 30-35 % of patients will become HCV
RNA negative after treatment, but only 15-
20% will have a sustained response once
therapy is stopped (3). With combination
therapy, the initial response rate increases to
50-55% and the sustained response after
treatment is completed is 35-45% (3). In
general, combination therapy should be
used unless there are contraindications to
the use of ribavirin.(See HIV 101 on page 8.)
Interferon alpha 2-a and alpha 2-b are given
subcutaneously three times a week in a dose
of 3 million units. Consensus interferon is
administered in a dose of 9 µm thrice week-
ly. A new formulation, pegylated interferon,
will be dosed once a week and leads to sus-
tained levels of interferon, which may
increase efficacy. Ribavirin is administered
orally in a dose of 1000 mg daily for those
who weigh less than 75 kg and 1200 mg
daily for those > 75 kg. Treatment with rib-
avirin may reduce fibrosis of the liver, which
slows advancement of liver disease (14).
(See HEPPigram on page 6 for an HCV
treatment algorithm.)
Treatment-associated side
effects
IFN side effects commonly include fatigue,
myalgias, headache, nausea, vomiting,
fever, irritability, and depression.
Hematological abnormalities, such as ane-
mia, are common. Severe adverse effects
include major depression, seizures, and
generalized bacterial infections (3). Dosing
IFN in the evening and pre-medicating with
ibuprofen is often used to reduce myalgias.
Decreasing the dosage of IFN may be help-
ful; severe side effects result in the discon-
tinuation of treatment in 5 to 10% of patients.
Paradoxical worsening of hepatitis may also
occur, and is thought to be due to an autoim-
mune response. Treatment should be dis-
continued in patients who have rising serum
ALT levels to greater than twice the baseline. 
Ribavirin can produce hemolytic anemia,
which can be life threatening in patients who
have heart disease and cerebral vascular
disease. Close monitoring of the patient and
blood counts are imperative. Ribavirin can
also cause fatigue, pruritus, rash, and nasal
stuffiness. Furthermore, ribavirin is terato-
genic, and therefore contraindicated in
women patients who are considering becom-
ing pregnant and their male partners.
Sexually active women and men should use
birth control during treatment and for at least
six months after completion of a ribavirin
regime. A male prisoner leaving prison fewer
than six months after cessation of treatment
needs to be warned to avoid having unpro-
tected sex, leading to pregnancy with a
female partner, until risk of teratogenicity has
passed. 
The incidence and severity of side effects
can be very high. Since it can be difficult for
incarcerated patients to quickly access their
clinician, it is important to:
G spend time preparing the patient for the
potential side effects;
G consider following these patients in a
dedicated liver clinic; and 
G consider the use of a nurse or other
staff person to regularly check in with
patients who are receiving HCV treatment
so that side effects can be rapidly
addressed.
June 2000     Volume 3, Issue 6 visit HEPP News online at www.hivcorrections.org 2
The Correctional
Doctors Dilemma... 
(continued from page 1)
Continued on page 4
80%
70%
60%
50%
40%
30%
20%
10%
0%
CA CT CO MA MD TX VA
54%
40%
32% 30% 28%
38% 37%
28%
40%
WA
Women
Men
All Inmates40%
Figure 2. Percentage of HCV Infection Among Inmates: Available Data
Table 1. HCV Testing is Recommended for the Following Persons
This figure shows the prevalence of HCV in certain state correctional populations.  Percentages are
shown by gender were data were available. These prevalence studies are not necessarily comparable
across states because different methods were used to compile the data.  HCV prevalence in reporting
states is the following; California: 40% of men and 54% of women (6); Connecticut: 32% of women (7);
Colorado: 30% (8); Maryland: 38% (9); Massachusetts: 27.5% (Hamden County) (10); Texas: 28% of
the men and 37% of women (4); Virginia: 30-40% (11);  Washington: 30-40% (12).
Source Consulted: Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection
and HCV-Related Chronic Disease. MMWR October 16, 1998: 47(RR19);1-39
Persons who should be tested routinely for hepatitis C virus (HCV) infection include:
G Persons who have injected illegal drugs, including those who injected once or a few 
times many years ago and do not consider themselves drug users. 
G Persons who were ever on chronic hemodialysis.
G Persons with persistently abnormal alanine aminotransferase levels. 
G Persons diagnosed with HIV infection.
G Sexual partners of persons diagnosed with HIV infection.
G Persons residing in correctional facilities.
G Persons who received a transfusion of blood or blood components before July 1992. 
and persons who received an organ transplant before July 1992. 
G Healthcare, emergency medical, and public safety workers after needle sticks, 
sharps, or mucosal exposures to HCV-positive blood.
Dear Colleagues,
To treat, or not to treat? That is the question currently faced by correctional clinicians who pro-
vide care to incarcerated hepatitis C (HCV) infected patients.   
This month’s main article is an update on last year’s issue by Dr. Anne Spaulding on HCV/HIV
co-infection. (July/August 1999) The good news is that response rates to dual therapy for hepati-
tis C are greater than anticipated, particularly among patients who were formerly considered to
have "untreatable" (stage 4) HCV. Furthermore, patients who respond to therapy after the first six
months of treatment tend to continue to do well, whether concurrently HIV infected or not. 
However, potentially severe treatment side effects such as depression and bone marrow sup-
pression (both of which can be particularly dangerous in the correctional setting) have dampened
some clinicians’ enthusiasm for treatment. Furthermore, incarcerated patients who are consid-
ered likely to continue to drink alcohol, use drugs, and who may be re-exposed to recurrent HCV
infection after release from prison are usually considered poor candidates for treatment, particu-
larly where treatment resources are limited.
Therefore, when considering HCV treatment the correctional physician must ponder (1) correc-
tional health system policy; (2) clinical guidelines for selecting patients for treatment; (3) risks ver-
sus benefits of treatment and (4) the individual patient’s profile. As a result, most correctional clin-
icians currently treating HCV-infected individuals consider the initiation of HCV treatment on a
case-by-case basis. 
After reviewing this issue, readers should be able to provide a synopsis of current views on the
pathogenesis of HCV infection, and identify current guidelines for initiating therapy and manag-
ing HCV treatment in incarcerated patients with or without concurrent HIV infection. Additional
information on existing treatment regimens for hepatitis C is provided in HIV 101, and  a flow dia-
gram describing one approach to initiating treatment is provided in our Heppigram.
Next month newsletter editorial assistant, Betsy Stubblefield will carry the July issue of HEPP
News with her to the International Conference on AIDS in Durban, South Africa. She’ll give you a
front line report after her return in the August issue.
Send us your comments and requests for information. If you wish, we’ll print your requests for
information in the HEPP News July 2000 International issue. Be sure to provide an email address
or mailing address, and get set to receive feedback from all over the world!
Sincerely,
Anne S. De Groot, M.D. Joseph Bick, M.D.
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4Without a good support system, a high per-
centage of patients will fail to complete thera-
py.  Because of the high cost of treatment,
time spent preparing patients and supporting
them while on treatment is likely to be cost
effective.*
Other interventions that are thought to be
helpful for the management of HCV include
hepatitis A (HAV) vaccination (8).
Superinfection with HAV may be associated
with fulminant liver failure in HCV patients.
For similar reasons, HBV vaccination is also
recommended if the patient is not previously
immune. (see HEPPigram, page 6).
HIV and HCV Co-infection
Analyses of the effect of HCV and HIV co-
infection on progression of either disease are
often confounded by concurrent risk factors
for progression. However, available data
seems to indicate that HIV infection may
worsen HCV liver disease. Persons who are
co-infected (HIV and HCV) appear to have a
12 to 300 fold higher risk of developing hepa-
tocellular carcinoma than non-carriers (15).
Furthermore, antiretroviral agents can con-
tribute to liver inflammation, and this may be
more frequent in those who have underlying
chronic hepatitis due to HCV or HBV (1).
The impact of HCV infection on HIV infection
is less clear. In some studies, HCV infection
does not appear to have an effect on the pro-
gression of HIV (16).  Other studies have
reported an association between more rapid
progression to AIDS or death in HIV-infected
patients; particularly among those who were
co-infected with HCV genotypes 1a and 1b
(17, 18).
HCV treatment in those who also have HIV
infection can be as successful as in non-HIV
infected individuals (19). In contrast, treat-
ment of HIV infection may be more difficult to
manage in patients who have HCV co-infec-
tion, as hepatotoxicity to anti-HIV therapy
appears to be more common among these
individuals. Therefore, patients who are co-
infected with HCV and HIV might benefit from
sequential treatment of their infections (20). In
many cases, it is better to control HIV infec-
tion and restore the immune system first.
Following successful HCV treatment, co-
infected patients are not more likely to relapse
after HCV treatment than  patients who do not
have concurrent HIV infection (19, 21).
Currently, treatment of hepatitis C, where
exclusionary criteria are not present, is rec-
ommended for patients when CD4 and viral
load values reflect good response to anti-
retroviral treatment. Although some contro-
versy remains in regard to the definition of a
good response to HAART, a stable CD4 T cell
count greater than 400 with an undetectable
viral load is generally accepted. 
Cost benefit analyses
With the high prevalence of HCV infection
among incarcerated individuals, there is a
concern that treatment of HCV could over-
whelm some system’s healthcare budgets.
Some cost benefit analyses, however, have
provided data in favor of treatment of those
with HCV. A recent decision analysis per-
formed by Wong demonstrated that six
months of therapy with interferon alpha result-
ed in a net savings in the range of $400 to
$3,500 over the lifetime of each patient  (22).
Dr. Wong’s analysis ranked interferon
treatment in the same range of cost effective-
ness as stool guiac testing, pneumococcal
vaccination, coronary bypass surgery, and
mammography.  
The analysis did not include cost data for
combination therapy with interferon and rib-
avirin, a more effective intervention for HCV,
which might yield even more favorable sav-
ings estimates. More recently, Wong suggest-
ed using the three month outcome of treat-
ment as a test for response This approach
may be less expensive and easier to imple-
ment in correctional settings, and he found (in
a non-correctional model), to do so would
reduce the cost of managing patients with
chronic HCV, without any detrimental impact
on patient outcomes (23).  
Conclusion
As with many other chronic medical condi-
tions, much of the morbidity and mortality
attributable to HCV does not manifest itself
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(continued from page 2)
Table 2. Factors Associated with
Sustained Response to aIFN Therapy
G early normalization of ALT levels 
G low serum HCV-RNA levels
G HCV genotype other than genotype 1
G mild chronic hepatitis on liver 
G biopsy age<45 years
*The 1997 consensus statement, which includes extensive discussions of the natural history of HCV, diagnosis, and treatment, can be found at the following
internet website: http://odp.od.nih.gov/consensus/cons/105/105_intro.html.
Table 3. Suggested Inclusion Criteria for Hepatitis Treatment in Prisons^
Source consulted:  MMWR 1998, October 16. 47 (RR19).
G Persistently elevated ALT levels
G Detectable HCV RNA
G A liver biopsy indicating either portal or bridging fibrosis or at least moderate
degrees of inflammation and necrosis (For more discussion of the necessity of the
liver biopsy, see Wong J. Cost effectiveness of ribavirin/interferon alpha-2b after inter-
feron relapse in chronic hepatitis C. Am J Med. 2000 Apr 1; 10895): 366-73.)
G No infractions for illicit alcohol or drug use
G Commitment to discontinue alcohol or drug use
G Control of major medical illnesses, including HIV infection 
(CD4+ count usually >400)
G Good control of any psychiatric illness, especially depression
G Age >18 and <60
G Pregnancy test negative
G Depending on genotype, length of stay in prison > 6-12 months from initiation of
treatment (if after care cannot be ensured, some systems may require a longer stay)
G No signs of decompensated liver disease
G Transaminases greater than upper limits of normal
G Platelet count >75,000/mL
G Hematocrit >30%, albumin >3.5mg/dL, creatinine <1.5 mg/dL, INR* <1.2
G Thyroid function tests normal, no elevated autoantibody titers (ANA, AMA)*
G Absence of advanced cirrhosis on liver biopsy
G Before treatment with ribavirin:
-No evidence of coronary heart disease
-Birth control, if conception possible (men and women)
-Women should have monthly pregnancy tests if conception is possible
Patients for Whom Treatment is Not Recommended:
Including those who do not meet the criteria described above as well as:
G Patients who have infractions for alcohol or injection drug use (Treatment should 
be delayed until these behaviors have been discontinued for >6 months.)
G Patients with major depressive illness, cytopenias, hyperthyroidism, renal 
transplantation, evidence of autoimmune disease, or who are pregnant.
^Some correctional facilities, such as the Adult Correctional Institute of Rhode Island, have
developed their own criteria.  
*INR= international normalized ratio;  ANA= antinuclear antibody; AMA=antimicrosomal 
antibody
Continued on page 5
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Rob Lyerla
HEPP News interviewed Rob Lyerla, PhD,  about the hepatitis C epidemic in our communities
and correctional facilities.  Dr. Lyerla is an epidemiologist in the Hepatitis Branch of the
National Center for Infectious Disease, Centers for Disease Control. 
HEPP News: Reports have found that 33% of all hepatitis C infected people pass through correctional
institutions each year. As you know, one of the biggest dilemmas for correctional healthcare providers is
whether or not to treat HCV infected inmates or to let them wait and seek treatment once they have
returned to the community. What would be the burden to correctional institutions if they decided to treat
eligible HCV patients?
Rob Lyerla: There are a number of considerations to account for in answering that question. Number
one- its presumptive to think that everyone who is antibody positive is eligible for treatment.  We have to
give responsibility to the primary care provider to decide if a person is eligible. To date, questions of eli-
gibility have not been answered on a national scale.  
The first question is, since HCV screening is voluntary, how many inmates want to be screened?  Some
studies say that as many as 40% will reject STD screening.  If such testing is not mandatory, we may
expect to see the same results with HCV testing.  Next, of those who agree to be screened, how many
are actually positive? Of those who test positive, how many are infected? Then, of those infected, how
many are eligible for treatment?
Treatment eligibility is not only a clinical decision.  History of injection drug use is an important consider-
ation.  Although not necessarily a contraindication, clinicians may advise against treatment if the patient
has not been through a treatment program. 
Another condition to consider is history of mental illness.  Federal Bureau of Prisons Medical Director
Newton Kendig says that 85% of his inmates have a history of mental illness.  In any given state you’re
likely to find that a prison has more mental health beds than the state mental health institutes.
Finally, it is important to ask if the inmate wants to be treated.  Side effects can be pretty severe.  Will the
patient be able to comply with  the treatment regimen? [For more inclusion criteria, also see main article].
After you have been through these eligibility criteria, you get down to a small number of people who are
eligible for treatment. This fact indicates to prison systems that HCV treatment may not be as big a finan-
cial burden as they think.
The important message to get across is that HCV patients should know how to protect themselves from
damaging their liver and progressing to cirrhosis.  They should also know how to avoid spreading it to
their partners and peers.
HN: Do you think public health departments recognize hepatitis C in prisons as a threat to the public
health?
RL: That depends on the state and the relationships that DOCs (departments of correction)  have with
departments of public health (DPH).  My own perception is that there should be a stronger relationship
between the two because clearly there is not a big jump between public health and public safety.  The
department of corrections is for safety, and the department of public health is for health and safety.
Partnerships between the two departments may greatly reduce the burden of disease on the public
health.  For instance, some of our research indicate that among those with acute hepatitis B infection
(HBV), 30% have a history of incarceration. Since 1981, we’ve recommended that inmates have HBV
vaccination, and some correctional systems have found ways to get funding from the state for vaccine
programs.  In some states, the DPH is working closely with juvenile detention centers to vaccinate young
offenders. Clearly, vaccinations in prisons would reduce morbidity outside the prison.  So I think it would
be beneficial to everyone involved to have corrections and public health work closely to reduce the bur-
den of disease in both the community and correctional setting.
HN: What do you think correctional care providers and inmates need to know about hepatitis in order to
reduce the burden of disease behind bars?
RL: I think there is a lot of misinformation out there. There is an onus of responsibility on the DOCs to be
up to date on treatment and management of HCV infection. It is not only inmates but staff people who
are ill-informed. HAV, HBV, and HCV are all diseases with which we must contend. We have to move peo-
ple beyond thinking that they’re at risk for only one disease. This population is at risk for a lot of illness-
es; syphilis, TB, HCV, HIV. Prisons and jails are a focal point of people with histories of high risk behav-
ior and infections. It falls on prison doctors and administrators to stay informed. Doing so might possibly
reduce the prevalence and spread of these infectious diseases in the general public.
until well after many infected inmates
have paroled.  Correctional systems
are faced with the dilemma of how to
prioritize treatment for HCV com-
pared to treatments for other expen-
sive medical conditions for which
there are more effective treatments
and oftentimes more imminent
sequelae. These concerns and the
limited efficacy of currently available
treatments for HCV have influenced
some correctional systems to adopt
highly restrictive inclusion and exclu-
sion criteria for HCV treatment (8,
10). While criteria based on medical
outcomes are clearly required, cor-
rectional physicians need to weigh
other exclusion criteria more careful-
ly, keeping in mind that a year 2000
dollar spent on treatment may
reduce the eventual cost (to society)
of caring for patients who may
require liver transplants in 20 to 30
years (10).
Treatment of HCV infection in HIV
infected patients also bears careful
consideration. It is currently standard
HIV care practice to screen all HIV
infected patients for viral hepatitis
antibodies. Screening does not need
to take place during incarceration if
prior records are obtained or if the
stay is brief.
In summary, the high prevalence of
HCV infection and the availability of
expensive treatments with limited
efficacy force difficult decision mak-
ing in correctional health facilities. In
community settings, most clinicians
now treat HCV infected patients
who meet treatment criteria with
combination IFN/ribavirin therapy.
Guidelines for the selection of
patients who are candidates for ther-
apy in correctional settings have
been developed but not widely
adapted.  Correctional facilities are
urged to adopt guidelines for priori-
tizing whom will receive HCV thera-
py. Cost-sharing between correction-
al facilities and public health is a
subject that needs to be explored,
particularly if 30% of all people with
HCV in the community cycle through
correctional facilities. Treatment of
these individuals to reduce HCV
morbidity and mortality will have
broad implications for general public
health.
Correctional
Doctors
Dilemma... 
(continued from page 4)
Continued on page 6
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HEPPigram
Management of HCV Treatment
EIA indicates patient
has HCV infection
Reduced HCV/RNA
normal  LFTs
Detectable HCV/RNA
Abnormal ALT
Stop Treatment
Sentence >6-12 months
(see Table 3, main article)
Evaluate candidate for treatment using exclusion 
criteria from table 3 of the main article. 
At 3 months, measure HCV, RNA and LFTs.
HCV, RNA undetectable
LFTs normal
Continue to monitor LFTs
and HCV RNA viral load
Rule out other causes of
elevated LFTs.
Check HCV genotype
Initiate treatment
G Discuss with patient goals of treatment and side effects, which can be considerable.
G Discuss their commitment to avoiding risky behaviors.
Follow in clinic @ weeks 1, 2, 4, then every month for symptoms, side effects, 
CBC, AST/ALT.
Continue Treatment, Check @ 6 months: If HCV genotype is 2 or 3, discontinue 
treatment. If HCV genotype is 1a or 1b, continue treatment for 6 months.
After treatment, if HCV RNA is negative, repeat HCV RNA
and transaminases every 2-6 months.
Exclude
Sentence <6 months
(see Table 3, main article)
* Consultant: Agouron Pharmaceuticals, 
Bristol-Myers Squibb
Speakers Bureau: Agouron Pharmaceuticals, 
Bristol-Myers Squibb, Glaxo Wellcome
**Consultant: Agouron Pharmaceuticals, 
Bristol-Myers Squibb
Speakers Bureau: Agouron Pharmaceuticals, 
Bristol-Myers Squibb
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Correctional
Doctors Dilemma... 
(continued from page 5)
5th  New England Correctional Health
Care Conference: Integrating
Correctional and Public Health
June 28, 2000
Sturbridge, MA
Sturbridge Host Hotel & 
Conference Center
CME credit available.
Call: 781.890.3434
Fax: 781.890.2766
Email: chcc@icg-ps.com.
2000 American Correctional
Association (ACA) Summer Congress
August 14-16, 2000
San Antonio, TX
Call: 800.222.5646, ext. 1922 
Fax: 1-301-918-1900
Visit: www.corrections.com/aca
24th National Conference on
Correctional Health Care 
September 9-13, 2000 
St. Louis, MO
Cervantes Convention Center 
CME credit available.
Call: 773.880.1460
Fax: (773) 880-2424
Email: ncchc@ncchc.org
Visit: www.ncchc.org
HIV/AIDS Behind Bars
Call for Abstracts.
HEPP News is sponsoring a pre-confer-
ence colloquium at the NCCHC confer-
ence listed above that will discuss the
outcomes of HIV education and preven-
tion interventions in correctional settings.
Accepting 500-word abstracts until
August 7. Please fax or e-mail questions
to Matt Stark: fax: 401-863-1243;
matthew_stark@brown.edu.
United States Conference on AIDS
(USCA)
Sponsored by the 
National Minority AIDS Council (NMAC)
October 1-4, 2000
Hyatt Regency
Atlanta, GA
Early Bird Registration Ends June 30th
Scholarship Applications Due June 30th
Contact: Oscar Medrano 
at omedrano@nmac.org
202.483.6622 ext. 343
http://www.nmac.org/usca2000/
default.htm
HEPP News and NMAC will be hosting a
morning seminar at USCA addressing
how to enact improvement plans for 
HIV  care in corrections.
Management of HIV/ AIDS in the
Correctional Setting: A Live Satellite
Videoconference Series, Antiretroviral
Update 2000
October 3, 2000
12:30- 3:30 E.S.T.
2.5 CME credits available
Call: (518) 262-6864
Email: santosm@mail.amc.edu
Save the 
Dates
News Flashes
HCV Management in Corrections:
Medical Director of FBOP Weighs In
In the May issue of Preventive Medicine in
Managed Care, Medical Director of the Federal
Bureau of Prisons, Newton Kendig, published
his recommendations for HCV management in
correctional settings.  The article details risk
factors for HCV infection, counseling and
screening strategies, indications for drug thera-
py, evaluating inmates for treatment, monitoring
inmates during treatment, and release planning.
(Kendig N. Hepatitis C Management in
Correctional Facilities.  Prev Med in Managed
Care.  2000, May. 1(1): S33-S41.)
Recent Study Supports
Combination Interferon Alpha and
Ribavirin
In the May issue of AIDS, researchers released
promising results from a study involving 20 co-
infected people treated with combination inter-
feron alpha (IFN) and ribavirin. All subjects
received 500 or 600 mg of ribavirin twice daily
in combination with intravenous interferon alpha
2b at a dose of 3 million units three times per
week. After six months of therapy, 10 subjects
had undetectable HCV levels in their blood and
the group’s average liver enzyme levels had
dropped significantly.  Researchers conclude
that combination therapy with IFN and ribavirin
provides effective and safe therapy to some
patients living with both HIV and hepatitis C.
Further research is indicated to determine the
sustainability of interferon-ribavirin combination
therapy over the long-term. (AIDS 2000
14(7)839-844.)
Testing May Predict Hepatitis C
Virus Outcome
Hepatitis C infection can lead to liver failure or
liver cancer, and a small study now suggests it
may be possible to predict which cases develop
into chronic infections.  Researchers studied 12
people with hepatitis C, focusing on the genet-
ics of the virus after infection.  According to a
report in the journal Science, the researchers
identified genetic changes that could help pre-
dict whether or not the infection would go away.
The body is able to rid hepatitis C on its own in
about 15 percent of cases, and the study found
significant genetic changes in the virus during
the early stages of infection for people whose
disease would become chronic. (Science
2000;288:339-344).
Increasing Percentage of HIV-
Related Deaths in the US Have
Associated Liver Disease
10% of those with HIV who died in 1997 had
liver disease as death co-factor, mostly due to
hepatitis virus co-infection or HAART or both.
Researchers from the Centers for Disease
Control and Prevention (CDC) have reported
that an increasing percentage of deaths in per-
sons with HIV in the US have at least one form
of liver disease as a co-factor. While not directly
shown to be the cause, the vast majority appear
to be  associated with hepatitis virus co-infec-
tion or HAART.  Virtually all of the viral infec-
tions would be due to either hepatitis B or
hepatitis C. The researchers used death
certificate information from all 50 states and
the District of Columbia from 1987 to 1997.
(10th International Symposium on Viral
Hepatitis and Liver Disease April 9-13, 2000,
Atlanta, Georgia).
Prisoners With AIDS, HIV Return at
High Rate
An Arkansas DOC Medical Services official,
Max Mobley, reported in May that 26 of the 35
HIV-infected inmates released in 1999 recently
returned die to parole violations or new offens-
es. In a newspaper report, Mobley stated that
he believes these HIV infected individuals have
trouble paying for their medications on the out-
side, causing them to commit the offenses that
send them back to prison.  According to DOC
spokeswoman Dina Tyler, the Arkansas DOC is
considering the construction of a "Special
needs" facility for geriatric, chronically ill, men-
tally ill and HIV/AIDS patients at a medium
security prison planned for Malver, AR.
(George, Emmett. Arkansas Democrat-Gazette
Online (www.ardemgaz.com) 05/18/00).
Correction: Nelfinavir Mesylate
(Viracept)
In the April issue of HEPP News we incorrectly
printed the new formulation of Nelfinavir mesy-
late (Viracept, available from Agouron).  The
new tablet form of Nelfinavir mesylate (1250mg
BID, 5 tablets) is film coated, not gel coated.
The distinction is important for some patients
who may not tolerate gel coatings.
July HEPP News
Next month we’ll put our finger on the pulse
of HIV care in correctional settings outside
the US, as we take you on our first annual
"world tour" of HIV in corrections.
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Coming Next Month . . .
Therapy
Monotherapy
Combination
Therapy
Form
alpha-2a, alpha-2b, 
consensus interferon*
alpha-2a, alpha-2b, 
consensus interferon
+
ribavirin: oral antiviral
agent
Dose
3 million units 
(MU)/injection;consensus
interferon 9µg/injection.
3 million units 
(MU)/injection;consensus
interferon 9µg/injection.
200mg capsules
(1000mg/day for <75kg;
1,200mg/day for >75kg)
Frequency
3x week subcutaneous
3x week subcutaneous
2x day
H
IV
 
1
0
1
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Therapy Commonly Used in HCV Treatment
HCV Related WEBSITES:
National Institute of Diabetes and Digestive and Kidney Disease 
http://www.niddk.nih.gov
National Center for Infectious Disease, Hepatitis Branch
http://www.cdc.gov/ncidod/diseases/hepatitis/
The Hepatitis Information Network
www.hepnet.com
Abstracts and Summaries of the 10th International Symposium
on Viral Hepatitis and Liver Disease (April 9-13, 2000, Atlanta,
Georgia) available at:
www.hivandhepatitis.com  (Conference website is www.hep2000.com)
Hepatitis: HealthlinksUSA
http://www.healthlinkusa.com/Hepatitis.html
Medline Plus Health Information on Hepatitis C
http://www.nlm.nih.gov/medlineplus/hepatitisc.html
Patient’s Guide to HIV Medicines and Guidelines for Their Use
November 1999  is a pamphlet produced by the National Minority AIDS Council (NMAC)  that providers may wish to make available to their patients.
The 23 page pamphlet is a comprehensive guide in both English and Spanish.  Free copies are available through NMAC at 202-483-6622.
Hepatitis C: Current Treatment Option and HIV Interactions
an online speech and slideshow given by Douglas T. Dieterich, MD Clinical Associate Professor of Medicine, New York University.  This talk is available
online at http://HivInsite.ucsf.edu.  Software to hear the talk can also be downloaded at this site.
NEJM Review of USPHS/IDSA "Prophylaxis Against Opportunistic Infections in Patients With Human Immunodeficiency Virus Infection."
The USPHS/IDSA guidelines for prophylaxis against opportunistic infections in patients with HIV, released in the Morbidity and Mortality Weekly Report
last August, are now available in the New England Journal of Medicine.  Dr. Joseph Kovacs and Henry Masur review the guidelines and provide a per-
spective that incorporates recent developments and principals they believe should be used to guide clinicians through the care of OIs in HIV infected
patients.  Kovacs JA, Masur H. NEJM 2000, May 11; 342 (19) 1416-1429; (www.nejm.org).
Resources
*Reserve for patients who have contraindications to ribavirin.
Monitoring 
Hgb / Hct - weeks 1,2 and 4, then monthly
WBC w/diff - weeks 1,2, and 4, then monthly
Platelet count - weeks 1, 2, and 4, then monthly
ALT- monthly
Serum chemistries and renal function studies - monthly
Thyroid-stimulating hormone - every 3 months
Other signs to monitor include CBCs - anemia, thrombocytopenia,
and leukopenia with dual therapy.
Duration of Treatment
Interferon monotherapy: 48-weeks, regardless of genotype. 
Combination therapy depends on viral genotype:
G HCV genotype 2 or 3:  24-week course of combination therapy  
yields results equivalent to those of a 48-week course. 
G HCV genotype 1:  48-week course yields a significantly better 
sustained response rate. 
Some experts advocate discontinuation of interferon monotherapy at
3 months if HCV RNA is still detectable or abnormal ALT. For Type I,
continue dual therapy only if HCV RNA is negative at 24 weeks.
Expected Response: Combination Therapy versus
Monotherapy
Sustained response: HCV RNA remains undetectable for 6 months
or more after therapy stops.
Combination therapy consistently yields higher rates of sustained
response than monotherapy. Combination treatment is more expen-
sive and is associated with more side effects than monotherapy, but,
in most situations, it is preferable. Factors that increase the likeli-
hood of a response to therapy include non-type-1 genotype, a low
baseline HCV RNA, age <45, gender (women show more success
than men), and mild chronic inflammation on liver biopsy.
Monitoring Post-Therapy
Repeal ALT and HCV RNA 6 months after completion of full course
of treatment.
Drug Interactions with Ritonavir
Hepatotoxicity can occur in association with antiretroviral therapy,
depending on which medication is being used. Sulkowski, et al.,
found that patients on ritonavir had a five-fold higher risk for hepato-
toxicity. (16) Their data indicate that antiretroviral-associated hepato-
toxicity should be considered according to specific medication rather
than drug classification or mechanism of action. 
Adapted from Chronic Hepatitis C: Current Disease Management. NIH Publication No. 99-4230, May 1999. www.niddk.nih.gov.
Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of
the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through 
July 31, 2000. The estimated time for completion of this activity is one hour and there is no fee for participation.
There may be more than one correct answer for each question.
Make sure you indicate all of the correct answers.
1. What percentage of patients infected with HCV are asympto-
matic?
a)  9%
b)  20%
c)  55%
d)  72%
e)  80%
2.  What percentage of annual deaths from liver disease are
caused by HCV?
a)  1.8%
b)  4%
c)  15%
d)  20%
e)  40%
3.  Non-responders to combination therapy can be identified by
checking HCV RNA after __ months of therapy.
a)  1
b)  2
c)  4
d)  6
e)  12
4.  It is important to know the genotype of your patient’s hepatitis
C virus because genotype helps determine
a)  successful response to therapy.
b)  when to measure ALT and HCV RNA levels when 
monitoring the patient.
c)  when to discontinue therapy in the context of non-
response.
d)  when to discontinue therapy in the context of response.
5.  Which of the following statements is false?
a)  Detectable response to HCV treatment may take four or 
five months to achieve, but those who fail to respond at 
3-6 months are unlikely ever to respond.
b)  A male prisoner leaving prison less than six months 
after cessation of treatment needs to be warned that impreg-
nating a woman before that time might lead to teratogenicity. 
c)  If your patient has HCV I, positive response to treatment 
at 6 months should be followed by an additional months of 
treatment and monitoring.
6.  Which of the following statements about HIV and HCV 
co-infection is false?
a)  Available data indicates that HIV infection may worsen 
HCV liver disease.
b)  Ritonavir has no significant effect on hepatoxicity.
c)  Response to HCV antiviral therapy in HCV patients with 
HIV appears no different than that of people not infected 
with HIV. 
BROWN UNIVERSITY SCHOOL OF MEDICINE  OFFICE OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor 
continuing medical education activities for physicians.  
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, 
recommendations and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or 
speak for the Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
HIV 101 5  4  3  2  1   5  4  3  2  1   
Spotlight 5  4  3  2  1   5  4  3  2  1   
Save the 5  4  3  2  1   5  4  3  2  1   
Dates
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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